T-cell agents in the treatment of rheumatoid arthritis: 2011 update

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 230-232

  Solomon, Gary E ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; PLACEBO; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; HUMAN; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 80054103730     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Solomon, GE., T cell agents in the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2010;68(3)162-165.
2. Genovese M, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: A phase IIIb non inferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011 May 25. DOI 10.1002/art.30463. [Epub ahead of print].
3. Kaine JL, Gladstein G, et al. Subcutaneous abatacept is well tolerated, demonstrates clinical efficacy and is associated with low immunogenicity following withdrawal and reintroduction: Phase III evaluation in rheumatoid arthritis patients responding to abatacept. Poster FRI0366. Presented at EULAR May 25-28, 2011, London, England.
4. Mease P, Genovese M, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six month multi-center, randomized, double blind, placebocontrolled, phase II trial. Arthritis Rheum. 2011;63(4)939-948.
5. Mease P, Genovese M, et al. Abatacept in the treatement of psoriatic arthritis: 12 month results of a phase II study. Abstract1919. Presented at the American College of Rheumatology annual meeting, Atlanta, Georgia, 2010.
6. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24 week pilot study. Ann Rheum Dis. 2011;70(6):1108-10.
7. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life threatening manifestations of systemic lupus erythematosus:results of a twelve-month, multicenter,exploratory, phase IIb, randomized, double blind, placebo controlled trial. Arthritis Rheum. 2010;62(10):3077-87.
8. Harrold L, Reed G, et al. Comparative Persistence and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-naïve rheumatoid arthritis patients using the CORRONA registry. Abstract 1794. Presented at the American College of Rheumatology annual meeting, Atlanta, Georgia, 2010.
9. Leffers HC, Ostergaard M, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70(7):1216-22.
10. Ribeiro A, Guedes L, et al. Abatacept in association with traditional DMARDS severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients. Presented at EULAR, May 25-28, 2011, London, England. Poster FR10342.
11. Alvarez-Quiroga C, ABud-Mendoza C, Doniz-Padilla L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol. 2011 Apr 13. [Epub ahead of print].